Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Preperitoneal Space in Hernia Repair.

Frontiers in surgery·2022
Same author

Detection of blood and DNA traces after thermal exposure.

International journal of legal medicine·2019
Same author

Antimicrobial peptides derived from the cartilage.-specific C-type Lectin Domain Family 3 Member A (CLEC3A) - potential in the prevention and treatment of septic arthritis.

Osteoarthritis and cartilage·2019
Same author

Using machine learning to advance synthesis and use of conservation and environmental evidence.

Conservation biology : the journal of the Society for Conservation Biology·2018
Same author

Detection of blood and DNA traces after thermal exposure.

International journal of legal medicine·2017
Same author

Erratum to: Blood Trace Evidence on Washed Textiles - a systematic approach.

International journal of legal medicine·2017

Related Experiment Video

Updated: May 19, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

H Andresen1, C Augustin, T Streichert

  • 1Institute of Legal Medicine, Forensic Toxicology, University Medical Center Hamburg-Eppendorf, Butenfeld 34, 22529, Hamburg, Germany. h.andresen@uke.uni-hamburg.de

International Journal of Legal Medicine
|August 18, 2012
PubMed
Summary

Genetic polymorphisms in cytochrome P450 (CYP) enzymes can alter drug metabolism. This pilot study found toxicogenetics moderately relevant in forensic cases, with genetic testing occasionally providing crucial insights into drug metabolism discrepancies.

More Related Videos

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS
10:13

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Related Experiment Videos

Last Updated: May 19, 2026

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS
10:13

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Area of Science:

  • Forensic Toxicology
  • Pharmacogenetics
  • Clinical Chemistry

Background:

  • Genetic variations in cytochrome P450 (CYP) enzymes influence drug metabolism.
  • Genotype-based dosing is crucial in pharmacotherapy.
  • The utility of genetic testing in forensic investigations is under exploration.

Purpose of the Study:

  • To evaluate the routine application of genetic polymorphism testing in forensic cases.
  • To investigate if CYP2D6 and CYP2C19 genetic variations explain unusual drug metabolite ratios.
  • To assess the impact of genetic factors versus drug-drug interactions in forensic casework.

Main Methods:

  • Screening of routine forensic cases (2004-2008) for unusual parent compound to metabolite (P/M) ratios.
  • Genotyping for CYP2D6 and CYP2C19 polymorphisms using Roche AmpliChip.
  • Gas chromatography/mass spectrometry (GC/MS) for drug analysis when needed.

Main Results:

  • Eleven samples showed conspicuous P/M ratios.
  • Identified CYP2D6 poor metabolizers (PM) and intermediate metabolizers (IM).
  • Identified CYP2C19 intermediate metabolizers (IM); only one case was clearly explained by genetic polymorphism, with drug-drug interactions being more frequent.

Conclusions:

  • Toxicogenetics has moderate overall relevance in forensic toxicology.
  • Intermediate metabolizer (IM) genotypes may be more significant than previously thought.
  • Genetic testing can provide valuable insights in specific forensic cases.